戻る Agenda
Session 2: UK Disclosure Requirements Updates'
Session Chair(s)
Scott Feiner
Senior Manager, Trial Disclosure
AbbVie, United States
In recent months, the United Kingdom’s disclosure requirements post-Brexit have come into greater focus.
This session provides updates from the HRA on their disclosure requirements, and a sponsor perspective on using the latest guidance documents to meet the clinical trial disclosure requirements of the UK.
Speaker(s)
Expanding Disclosure Requirements From the HRA
Naho Yamazaki, PhD
Health Research Authority, United Kingdom
Deputy Director, Policy and Partnerships
Example of Interventional, Non-Interventional and Device Trials A Sponsor Walkthrough of UK Clinical Trial Disclosure Guidance
Joyce Swart
Alcon Research, LLC, United States
Director, Clinical Trial Disclosure